Southern Acids (malaysia) Bhd. · MYX:SAB

Southern Acids (malaysia) Bhd — Southern Acids (M) Berhad — Shareholder Meeting (August 2021)

16 slides from Southern Acids (malaysia) Bhd's shareholder meeting presentation, Aug 27, 2021

  1. Slide 1: Southern Acids (M) Berhad 40th Annual General Meeting

    SOUTHERN ACIDS (M) BERHAD 40TH ANNUAL GENERAL MEETING 27 AUGUST 2021 SHAREHOLDERS BRIEFING

  2. Slide 2: Source of Information & Disclaimer

    SLIDE 1 SOURCE OF INFORMATION & DISCLAIMER Source of Information Used For The Presentation  The Company’s 2021 Annual Report; and  All other information that are available from Bursa Malaysia Securities Berhad’s website. Disclaimer Information contained in this presentation is intended solely for

  3. Slide 3: Presentation Contents

    SLIDE 2 PRESENTATION CONTENTS 1. Southern Acids (M) Berhad (“SAB or the Company”) & Its Subsidiaries (“SAB Group”) a. SAB Group’s Key Financial Highlights For The Financial Year Ended 31 March 2021 (“FY2021”); and b. SAB Group’s Financial Performance For The FY2021 2. SAB Group’s Segments a. Review

  4. Slide 4: SAB Group's Key Financial Highlights for FY2021

    SOUTHERN ACIDS (M) BERHAD SAB GROUP’S KEY FINANCIAL HIGHLIGHTS FOR FY2021

  5. Slide 5: SAB Group's Key Financial Highlights

    SLIDE 3 SAB GROUP’S KEY FINANCIAL HIGHLIGHTS FY2021 FY2020 (RM’000) (RM’000) Revenue 741,103 660,286 Profit Before Tax (“PBT”) 60,345 48,740 Profit For The Year 47,783 39,229 Earnings Per Share 27.3 23.4 Dividend (Net) 5.0 sen 5.0 sen Dividend Pay-out Ratio 14.3% 17.4%

  6. Slide 6: SAB Group's Key Financial Highlights (Cont'd)

    SLIDE 4 SAB GROUP’S KEY FINANCIAL HIGHLIGHTS (CONT’D) FY2021 FY2020 (RM’000) (RM’000) Total Assets 806,218 727,388 Net Current Assets 359,164 310,861 Total Liabilities 96,869 77,166 Equity Attributable To 637,662 594,422 Shareholders Of The Company

  7. Slide 7: SAB Group's Financial Performance (Cont'd)

    SLIDE 5 SAB GROUP’S FINANCIAL PERFORMANCE (CONT’D) FY2021 FY2020 Changes RM’000 RM’000 RM’000 Group’s Revenue 741,103 660,286 80,817 Group’s PBT/(Loss Before Tax) 60,345 48,740 11,605 (“LBT”) Segments’ PBT Milling & Estate 38,285 28,037 10,248 Healthcare 16,685 25,410 (8,725) Oleochemical (548) (3,2

  8. Slide 8: Review of the Respective Segments' Financial Performance

    SOUTHERN ACIDS (M) BERHAD REVIEW OF THE RESPECTIVE SEGMENTS’ FINANCIAL PERFORMANCE

  9. Slide 9: Oleochemical Segment Financial Performance

    SLIDE 6 OLEOCHEMICAL SEGMENT FINANCIAL PERFORMANCE FY2021 FY2020 Changes RM’000 RM’000 RM’000 Revenue 325,541 282,410 43,131 PBT/(LBT) Core LBT (2,138) (5,210) 3,072 Non-Core PBT 1,590 1,991 (401) (548) (3,219) 2,671 Highlights on core LBT The lower core LBT was due to higher revenue as a result of

  10. Slide 10: Oleochemical Segment Outlook & Prospects for FY2022

    SLIDE 7 OLEOCHEMICAL SEGMENT OUTLOOK & PROSPECTS FOR FY2022 Challenging, key factors are as follows:- 1. External factors;  Persisting challenges and uncertainties surrounding the global economy from the impact of the new variant of Covid- 19;  Disruptions to the plant activities due to the moveme

  11. Slide 11: Milling & Estate Segment Financial Performance

    SLIDE 8 MILLING & ESTATE SEGMENT FINANCIAL PERFORMANCE FY2021 FY2020 Changes RM’000 RM’000 RM’000 Revenue 312,545 269,453 43,902 PBT Core PBT 23,522 19,413 4,109 Non-Core PBT 14,763 8,624 6,139 38,285 28,037 10,248 Highlights on core PBT 1. The higher revenue was mainly contributed by an overall inc

  12. Slide 12: Milling & Estate Segment Outlook & Prospects for FY2022

    SLIDE 9 MILLING & ESTATE SEGMENT OUTLOOK & PROPECTS FOR FY2022 Challenging, the performance of this segment is largely subjected to the following uncontrollable factors:-  Persisting challenges and uncertainties surrounding the global economy from the impact of the new variant of Covid-19 ;  Commo

  13. Slide 13: Healthcare Segment Financial Performance

    SLIDE 10 HEALTHCARE SEGMENT FINANCIAL PERFORMAMCE FY2021 FY2020 Changes RM’000 RM’000 RM’000 Revenue 77,448 91,365 (13,917) PBT Core PBT 13,369 22,635 (9,266) Non-Core PBT 3,316 2,775 541 16,685 25,410 (8,725) Highlights on core PBT 1. Revenue was lower mainly due to the impact from the prolonged Co

  14. Slide 14: Healthcare Segment Outlook & Prospects for FY2022

    SLIDE 11 HEALTHCARE SEGMENT OUTLOOK & PROSPECTS FOR FY2022 Continue to enjoy stable growth  Persisting challenges and uncertainties from the impact of the new variant of Covid-19 remain a concern until the herd immunity is achieved by end of 2021  Continue to improve our service levels which inclu

  15. Slide 15: SAB Group's Outlook & Prospect for FY2022

    SLIDE 12 SAB GROUP’S OUTLOOK & PROSPECT FOR FY2022 In short, it remains challenging, especially due to concerns over the economic uncertainties, both locally and globally, in wake of the prolonged Covid-19 pandemic.

  16. Slide 16: Questions & Answers

    SOUTHERN ACIDS (M) BERHAD QUESTIONS & ANSWERS

Southern Acids (M) Berhad — Shareholder Meeting (August 2021) on 6ix